NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND. Fabrizio Parente

Similar documents
Implementation of disease and safety predictors during disease management in UC

Achieving Success in Ulcerative Colitis: the Role of Infliximab

Mucosal healing: does it really matter?

Op#mizing)Management)in)IBD:) Mucosal)Healing)

How to differentiate Segmental Colitis Associated with Diverticulosis and Inflammatory Bowel Diseases?

Predicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium

Mohamed EL-hemaly Gastro- intestinal surgical center, Mansoura University.

Mucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium

Ali Keshavarzian MD Rush University Medical Center

Positioning Biologics in Ulcerative Colitis

Treatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10

Page 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis

The Spectrum of IBD. Inflammatory Bowel Disease. Symptoms. Epidemiology. Tests for IBD. CD or UC? Inflamatory Bowel Disease. Fernando Vega, M.D.

Endoscopy in Inflammatory Bowel Disease DR. REENA KHANNA

Clinical Study Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis

Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy

Definitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)

Surgical Management of IBD. Val Jefford Grand Rounds October 14, 2003

INFLAMMATORY BOWEL DISEASE. Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic

Guided by Dr. Michal Amitai Head of Abdominal Imaging Department of Diagnostic Imaging Sheba Medical Center Sackler School of Medicine, Tel Aviv

Spectrum of Diverticular Disease. Outline

Randomised clinical trial: delayed-release oral mesalazine 4.8 g day vs. 2.4 g day in endoscopic mucosal healing ASCEND I and II combined analysis

Anti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis

Diagnostic and Therapeutic Approaches to Dysplasia in Inflammatory Bowel Diseases

Personalized Medicine in IBD: Where Are We in 2013

SURGICAL MANAGEMENT OF ULCERATIVE COLITIS

5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD

... Inflammatory disorder of the colon that occurs as a complication of antibiotic treatment.

What do we need for diagnosis of IBD

Response to First Intravenous Steroid Therapy Determines the Subsequent Risk of Colectomy in Ulcerative Colitis Patients

How do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD

The Role of Ultrasound in the Assessment of Inflammatory Bowel Disease

Surgical Management of IBD in the Age of Biologics

As clinicians we would all agree that the goal for our

Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?

Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists

Biologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College

Title: Author: Journal:

Perianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic

Endoscopy in IBD. F.Hartmann K.Kasper-Kliniken (St.Marienkrankenhaus) Frankfurt/M.

IBD What s in it for you?

Dr David Epstein Vincent Pallotti Hospital and University of Cape Town

INFLAMMATORY BOWEL DISEASE

Clinical Trials in IBD. Bruce Yacyshyn MD Professor of Medicine Division of Digestive Diseases

Mild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested. Philippe Marteau, Paris, France

Disease behavior in adult patients- are there predictors for stricture or fistula formation?

Endpoints for Stopping Treatment in UC

Pitfalls in the Diagnosis of Inflammatory Bowel Disease

Treatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG

11/13/11. Biologics for CD and CUC: The Impact on Surgical Outcomes. Principles of Successful Intestinal Surgery

Azathioprine for Induction and Maintenance of Remission in Crohn s Disease

European evidence-based consensus on the use of imaging techniques in inflammatory bowel disease diagnosis and management

Proctitis Workshop. PD Dr Michel H. Maillard, MD-PhD 1,2. Crohn s and Colitis Center, Gastroentérologie Beaulieu SA.

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

Ulcerative Colitis: Refining our Management and Incorporating Newer Concepts

Contrast-enhanced small bowel ultrasound in the assessment of the small bowel in patients with Crohn s Disease

Narrow band imaging efficiency in evaluation of mucosal healing/ relapse of ulcerative colitis

Ulcerative colitis (UC) is a. The Patient with Newly Diagnosed Ulcerative Colitis: Anticipating the Questions and Individualizing the Answers

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

Indications for use of Infliximab

DIVERTICULOSIS MEDICAL AND SURGICAL MANAGEMENT. Simon Radley Consultant Surgeon March 2013

Fistulizing Crohn s Disease: The Aggressive Approach

Evaluation of the severity of ulcerative colitis using endoscopic dual red imaging targeting deep vessels

A Case of Crohn s Disease with Mesalazine Allergy that was Difficult to Differentiate from Comorbid Ulcerative Colitis

Disease Monitoring. Symptoms Activity. No Symptoms No Activity. What is the Problem with Dogma? What are the FACTS

PEDIATRIC INFLAMMATORY BOWEL DISEASE

Inflammatory Bowel Disease and Surgery: What You Should Know

Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals

Inflammatory Bowel Disease When is diarrhea not just diarrhea?

Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation

Evaluation of treatment effect in UC and CD (children)

The role of Surgery and Stomas in IBD

Patho Basic Chronic Inflammatory Bowel Diseases. Jürg Vosbeck Pathology

An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD

Chromoendoscopy and Endomicroscopy for detecting colonic dysplasia

Diarrhoea for the Acute Physician

Long-term outcome after infliximab for refractory ulcerative colitis

Listed below are some of the words that you might come across concerning diseases and conditions of the bowels.

IBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants

Challenges in IBD: The Post-Op IBD Patient: Preventing Pouchitis & Recurrence

children Crohn s disease in MR enterography for GI Complications Microscopy Characterization Primary sclerosing cholangitis Anorectal fistulae

ד"ר דוד ירדני המכון לגסטרואנטרולוגיה ומחלות כבד מרכז רפואי סורוקה

Review article: the long-term management of ulcerative colitis

I nflammatory bowel diseases (IBD) are chronic intestinal

INFLAMMATORY BOWEL DISEASE

Surgery and Stomas in IBD When do I need it? Can I avoid it? How do I live with it?

Percent Cumulative. Probability. Penetrating. Inflammatory. Stricturing. Months Patients at risk N =

Pouchitis and Cuffitis A bloody mess. Sze-Lin Peng Colorectal Surgeon Counties Manukau District Health Board

Crohn s Disease. Resident Lecture 1/17/19

How to characterize dysplastic lesions in IBD?

Terumitsu; Nagayasu, Takeshi

IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital

Moderately to severely active ulcerative colitis

RE: Title: Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis

September 12, 2015 Millie D. Long MD, MPH, FACG

CCFA. Crohns Disease vs UC: What is the best treatment for me? November

Fujiya M, Saitoh Y, Watari J, Moriichi K, Kohgo Y.

Can We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA

CASE DISCUSSION: The Patient with Dysplasia: Surgery or Active Surveillance? Noa Krugliak Cleveland, MD David T. Rubin, MD

Transcription:

NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND Fabrizio Parente Gastrointestinal Unit, A.Manzoni Hospital, Lecco & L.Sacco School of Medicine,University of Milan - Italy

Mucosal imaging in IBD ITEMS Endoscopic visualization of ileo-colonic mucosa has a prognostic role during severe flare up of disease both in CD and UC. Mucosal healing after short-term medical therapies, as assessed by endoscopy, seems to be associated with a better prognosis in CD and, especially, in UC. Can Bowel Ultrasound be used as a surrogate of endoscopy in assessing mucosal response to medical therapies in UC?

Endoscopy and severe Ulcerative colitis Colonoscopy is feasible and safe in over 90% of severe attacks or flare-up of ulcerative colitis Severe endoscopic activity is based on: Deep ulcers Extensive loss of mucosal layer with or without residual mucosal areas Well-like ulcers Large mucosal erosions Colectomy was performed in 43/46 patients with severe endoscopic colitis as compared with only 9/39 with moderate endoscopic colitis (OR 41, 95%CI 10,5-164) Carbonnel F, et al. Dig Dis Sci 1994;39:1550-7

Endoscopy and severe ulcerative colitis Deep ulcers and severe endoscopic rectal inflammation at admission are significantly more common in patients who subsequently will require colectomy. Severity of endoscopical picture constitutes one of the most important predictors of refractoriness to intravenous steroids. Travis S, et al. Gut 1996;38:905-10

Endoscopy and severe ulcerative colitis Probability of colectomy-free survival according to the endoscopic severity of ulcerative colitis at presentation. Statistical significant difference (p=0,0001) Hazard Ratio 18,1 (95%CI 2,7-21,2) Daperno M, et al. Dig Liver Dis 2004;36(1):21-8

Endoscopic criteria of severity (ECS) according to anatomical severity (ACS) of colonic Crohn s disease ACS+ group ACS- group No. of patients 68 10 ECS 1 32 0 ECS 2 65 2 ECS 3 34 0 At least one ECS 95% 20% Nahon, Am J Gastroenterol 2002

Mucosal healing with biological therapies in CD By courtesy of Prof. Rutgeerts D Haens Van Assche, Leuven, Belgium

Endoscopic healing in CD reduces the risk of surgery and hospitalisation ACCENT I patients who demonstrated healing at one or both control visits had a lower incidence of hospitalisation or surgery *only intra-abdominal surgeries analyzed Rutgeerts Gastrointest. Endoscopy 2006; 63: 433-42

Mucosal healing in ulcerative colitis

Cumulative relapse risk based on mucosal healing at endoscopy after 5-ASA treatment Meucci G, et al. DDW 2006

Clinical remission of UC after 30 weeks according to mucosal healing at 8 weeks with Infliximab Rutgeerts P, et al. N Engl J Med 2005;353:2462-76

Long-term risk of colectomy according to mucosal healing after short-term treatment with Infliximab Kohn A, et al. Aliment Pharmacol Ther 2007; 26: 747-756

MUCOSAL HEALING IN ULCERATIVE COLITIS The key question is whether the mucosal healing itself is able to improve the outcome of the disease, and therefore if the clinical evaluation alone is not sufficient to monitor UC patients in clinical practice. Clear clinical guidelines based on endoscopic followup in UC are not yet available and, moreover, patients are reluctant to be re-endoscoped during follow-up because of the invasiveness of colonoscopy. Can bowel US be employed as surrogate of colonoscopy in evaluating mucosal healing in ulcerative colitis?

Bowel wall thickening seen at US in the cross section and longitudinal scans (ileal CD)

Current applications of Bowel ultrasound in IBD Primary imaging technique in patient with clinically suspected IBD (especially Crohn disease where conventional bowel US has sensitivity and specificity of 78-94% and 79-100%). Evaluation of anatomical distribution and extension of lesions along the bowel in an already known IBD both at primary diagnosis and during follow-up. Detection of abominal complications of IBD (especially strictures, fistulas and abscesses in CD, where sensitivities are 86%, 71% and 90%,respectively). Evaluation of local disease activity (favourable results with the aids of Power Doppler function and iv contrast agents).

Bowel US in active ulcerative colitis COLONIC WALL FEATURES Thickening: 5-8 mm Echopattern: stratified or hypoechoic (severe activity) Vascularity: often hypervascularization in flare-up Haustration: often absent SITE AND EXTENSION Rectum always involved (difficult to see at US) No skip areas Colite Ulcerosa EXTRAINTESTINAL ALTERATIONS Fibrofatty mesenterial proliferation: rare Lymph adenopathy: rare Worlicek et al. 87; Arienti et al. 99, Parente et al. 02

Significance of predominantly hypoechoic echopattern: correlation with histology and vascularity as detected by Doppler-US (resected colonic specimens) Parente, Alim Pharmacol & Ther 2005

Bowel vascularity, as assesssed by power Doppler US, in determing local inflammatory disease activity

Thickened bowel segment with greatly increased intramural blood flow as depicted by high definition Doppler US (e-flow technique)

Thickening of colonic walls with stratified echopattern and disappearance of haustra coli sigmoid and descending colon. Cross section Longitudinal US section

Complete disappearance of colonic haustration with thickening of colonic wall in a patient with UC flare-up (descending colon)

Parente F, Aliment Pharmacol Ther. 2003;18:1009-16

Thickening of rectal walls (visualized throughout the bladder window) in a patient with severe ulcerative proctitis

Relationship between US activity index, MRI activity index and endoscopic activity index (Baron) in UC Pascu M, Inflamm Bowel Dis. 2004;10:373-82

Endoscopical activity index of ulcerative colitis (Baron score) and US activity index of disease based on degree of colonic bowel thickening and presence of intramural blood flow at power Doppler US. Endoscopical activity index US activity index

US-activity index before and after 8 weeks of high dose steroids in pts with severe UC flare up Parente et al,uegw Berlin 2006

Study design Population: 83 patients with severe UC (all had moderate to severe disease graded 2-3 according to the Baron score) requiring high-dose steroids were recruited. Time 0 3 month 9 month 15 months UC pts Endoscopy Endoscopy Endoscopy Endoscopy Bowel US Bowel US Bowel US Bowel US Lab Lab Lab Lab Visit Visit Visit Visit

Severe: Truelove e Witts classification of ulcerative colitis Diarrhoea: 6 or more motions per day, with blood Fever: mean evening temperature > 37.5, or any time of day over 37.7 on at least 2 out of 4 days Tachycardia: mean pulse rate over 90 per minute Anemia: Hemoglobin of 75% or less, allowing for recent transfusion ESR: more than 30 mm in 1 hour Mild: Mild diarrhoea: less than 4 motions per day, with only small amounts of blood No fever No tachycardia Mild anemia ESR < 30 mm in 1 hour Moderately Severe Intermediate between mild and severe

Baron score for ulcerative colitis Grade 0 Lack of lesions. Normal vascular pattern Grade 1 Hyperemic mucosa. Mucosa granularity. Mucosal oedema. Indistinct vascular pattern. Grade 2 Mucosa friability. Contact bleeding. Superficial ulcerations. Free luminal blood or pus. Grade 3 Deep or coalescing ulcers. Spontaneous bleeding.

Material and methods Endoscopic severity of UC was graded 0-3 according to Baron score, US severity was also graded 0-3 according to the maximum colonic wall thickening and vascularity (grade 0: CTW < 4mm; grade 1: CTW 4-6mm; grade 2: CTW 6-8 mm,grade 3: CTW > 8 mm) Patients clinically responsive to steroids (slowly tapered within 4 mths) and then maintained on mesalazine 1.6-2.4 g/day were followed-up for 15 mths with repeated colonoscopy and bowel US at 3, 9 and 15 mths from entry. Statistical analysis Concordance between clinical, endoscopic and US scores at 0, 3, 9 and 15 mths was determined by kappa statistics. Unconditioned multiple regression analysis was used to assess predictivity of Truelove, Baron and US scores measured at 3 and 9 mths on the development of a UC relapse (Baron score 2-3) at 15 mths.

Distribution of 74 UC patients at baseline according to various selected variables

Concordance between Baron score (gold standard) and Truelove score at 3 months Baron score at 3 mths Truelove score at 3 months Frequency mild moderately severe severe Total 0-I 48 3 0 51 II 7 6 0 13 III 4 6 0 10 Totale 59 15 0 74 Statistics Value ASE 95% Confidence Intervals Kappa 0.3486 0.0911 0.1700 0.5272 Weighted Kappa 0.3795 0.0844 0.2140 0.5450

Concordance between Baron score (gold standard) and Truelove score at 15 months Baron score at 15 mths Truelove score at 15 mths Frequency mild moderately severe severe Total 0-I 48 1 0 49 II 6 6 1 13 III 1 5 6 12 Total 55 12 7 74 Statistics Value ASE 95% confidence intervals Kappa 0.5923 0.0858 0.4242 0.7604 Weighted Kappa 0.6868 0.0734 0.5430 0.8306

Concordance between Baron score (gold standard) and Ultrasound score at 3 months Baron score at 3 mths US score at 3 mths Frequency 0-1 2 3 Total 0-I 49 2 0 51 II 2 6 5 13 III 0 3 7 10 Total 51 11 12 74 Statistics Value ASE 95% Confidence intervals Kappa 0.6600 0.0774 0.5084 0.8117 Weighted Kappa 0.7622 0.0578 0.6488 0.8755

Concordance between Baron score (gold standard) and US score at 15 months Baron score at 15 mths US score at 15 mths Frequency 0-1 2 3 Total 0-I 48 1 0 49 II 0 12 1 13 III 0 3 9 12 Total 48 16 10 74 Statistics Value ASE 95% confidence intervals Kappa 0.8677 0.0542 0.7614 0.9740 Weighted Kappa 0.9042 0.0398 0.8263 0.9821

Ulcerative colitis Follow-up - Activity SEVERE ACTIVE DISEASE QUIESCENT DISEASE Increased wall thickness (> 6 mm) Hypoechoic echopattern of colonic walls Hypervascularization (increased Doppler sig.) Disappearance or reduction of haustration Normal wall thickness Stratified echopattern of colonic wall

Distribution of 74 patients with UC by Baron score at 15 months according to age, sex and various selected covariates. ^Estimated by unconditional multiple logistic regression models after allowance for smoking status (backward selection).

Distribution of 74 patients with UC, by Baron score at 15 months according to Baron and US score after 3 and 9 months. ^ Estimated by unconditional multiple logistic regression models after allowance for smoking status and appendicectomy (backward selection).

Conclusion I We confirm that not achieving complete mucosal healing after short-term treatment with high-dose steroids is predictive of negative outcome at 15 months. Therefore, the most important objective of any pharmacological therapy for active UC should be achieving endoscopic remission. Severe US score after short-term medical therapy is almost as accurate as endoscopic score in predicting negative disease outcome at 15 months.

Conclusion II Therefore, bowel US may constitute, in expert hands, an accurate surrogate of colonoscopy in order to assess response to treatment and may therefore be preferred to endoscopy in clinical practice, with the exclusion of diseases confined to the rectum only.

Thank you Dr Roberto Bianco Dr Laura Norsa Consultants Radiologist Dr Gianluca Sanpietro Consultant Surgeon Dr Pietro Zerbi Lecturer in Hystopathology

Conclusion Response to high-dose steroids based on clinical evaluation only at 3 mths from starting therapy fails to detect those steroid-dependent UC pts who still have endoscopic activity and are therefore at high risk of recurrence at 15 mths. Only bowel US at 3 mths, other than colonoscopy, may identify this subset of pts who require a more aggressive medical approach.

Oral-contrast enhanced bowel US

RESULTS Considering endoscopy as the reference test for good response to steroids, in the three visits we showed inconsistent concordance between 0-I Baron scores and Truelove score (weighted K ranged between 0.38 and 0.94), but high and consistent concordance between 0-I Baron scores and US scores (weighted K between 0.76 and 0.90).

RESULTS On logistic regression analysis, patients with high Baron score (2-3) at 3 months, regardless of their Truelove score, had a high risk of severe endoscopic activity at the 15 th months (OR 5.2; 95% CI: 1.6-17.6). Similarly, a significant direct association, was also shown between severe US scores (2-3) at the 3 rd and at the 15 th month (OR 9.1; 95% CI: 2.5-33.5);